Results 51 to 60 of about 31,793 (243)

Effect of Ticagrelor, a Cytochrome P450 3A4 Inhibitor, on the Pharmacokinetics of Tadalafil in Rats

Pharmaceutics, 2019
Tadalafil is a cytochrome P450 (CYP) 3A4 substrate. Because there are few data on drug-drug interactions, it is advisable to take sufficient consideration when co-administering tadalafil with CYP3A4 inducers or inhibitors.
Young-Guk Na, Jin-Ju Byeon, Hyun Wook Huh, Min-Ki Kim, Young G. Shin, Hong-Ki Lee, Cheong-Weon Cho   +6 more
doaj   +1 more source

Safety and efficacy of low-dose ticagrelor in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention

Platelets, 2022
It remains unclear whether low-dose ticagrelor offers better safety and similar efficacy for Asian patients with acute coronary syndromes (ACS). We aimed to compare the safety and effectiveness of low-dose ticagrelor vs standard-dose ticagrelor in ...
Yue Wang, Beibei Liu, Leilei Chen, Yue Wang, Zhiqiang Wang, Xiaojiang Zhang, Min Suo, Gary S. Mintz, Xiaofan Wu   +8 more
doaj   +1 more source

Prognostic Implication of CYP2C19 Genotype According to Clinical Risk Stratification After Drug‐Eluting Stent Implantation

Clinical Pharmacology &Therapeutics, EarlyView.
From the nationwide multicenter consortium, 8,163 patients undergoing drug‐eluting stent implantation were classified according to the presence of the CYP2C19 loss‐of‐function (LoF) allele: rapid or normal metabolizers (RMs/NMs) vs. intermediate or poor metabolizers (IMs/PMs), and clinical risk was stratified using the CHADS‐P2A2RC and TRS 2°P scores ...
Hyun Woong Park, Jae‐Hwan Lee, Jin‐Ok Jeong, Diana A. Gorog, Udaya S. Tantry, Byeong‐Keuk Kim, Hyung Joon Joo, Kiyuk Chang, Jin‐Yong Hwang, Young Bin Song, Sung Gyun Ahn, Jung‐Won Suh, Woong Gil Choi, Jung Rae Cho, Jeehoon Kang, Sang Yeub Lee, Hyo‐Soo Kim, Moo Hyun Kim, Do‐Sun Lim, Eun‐Seok Shin, Paul A. Gurbel, Young‐Hoon Jeong, on behalf of the PTRG‐DES Consortium Investigators   +22 more
wiley   +1 more source

Does the level of myocardial injury differ in primary angioplasty patients loaded first with clopidogrel and the ones with ticagrelor?

Anatolian Journal of Cardiology, 2020
Objective: In daily clinical practice, we encounter ST segment elevation myocardial infarction (STEMI) patients loaded with clopidogrel upon admission to primary angioplasty.
Nil Ozyuncu, Hüseyin Göksülük, Turkan Seda Tan, Kerim Esenboga, Yusuf Atmaca, Çetin Erol   +5 more
doaj   +1 more source

Ticagrelor Loading on ST-Elevation Myocardial Infarction: Interaction With Prodromal Angina on Infarct Size and Clinical Events

Journal of Cardiovascular Pharmacology and Therapeutics, 2023
Introduction: Ticagrelor might reduce infarct size by exerting a more potent antiplatelet effect or by promoting a potential conditioning stimulus in ST-elevation myocardial infarction (STEMI) patients.
João Pedro Faria MD, Pedro Oliveira PhD, André Alexandre MD, David Sá Couto MD, Ricardo Costa MD, Andreia Campinas MD, André Frias MD, Bruno Brochado MD, Raquel Santos MD, João Silveira MD, Severo Torres MD, André Luz MD, PhD, FESC   +11 more
doaj   +1 more source

Clinical implication of ticagrelor monotherapy in patients with small vessel coronary artery disease: results from the TICO randomized trial

Frontiers in Cardiovascular Medicine, 2023
BackgroundThe aim of this study was to evaluate the efficacy and safety of ticagrelor monotherapy in patients with small vessel disease compared with ticagrelor-based DAPT within the Ticagrelor Monotherapy after 3 Months in the Patients Treated with New ...
Jae Young Cho, Donghyeon Joo, Kyeong Ho Yun, Byeong-Keuk Kim, Myeong-Ki Hong, Yangsoo Jang, Seok Kyu Oh   +6 more
doaj   +1 more source

Assessing a 600-mg Loading Dose of Clopidogrel 24 Hours Prior to Pipeline Embolization Device Treatment [PDF]

, 2018
Background: Clopidogrel/aspirin antiplatelet therapy routinely is administered 7-10 days before pipeline aneurysm treatment. Our study assessed the safety and efficacy of a 600-mg loading dose of clopidogrel 24 hours before Pipeline Embolization Device ...
Atallah, MD, Elias, Bekelis, MD, Kimon, Chalouhi, MD, Nohra, Hasan, MD, David, Jabbour, Pascal, MD, Rosenwasser, MD, MBA, FACS, FAHA, Robert H., Saad, MD, Hassan, Smith, MD, Michelle, Tjoumakaris, MD, Stavropoula, Zarzour, MD, Hekmat   +9 more
core   +2 more sources

The in‐hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta‐analysis

ESC Heart Failure, Volume 12, Issue 2, Page 998-1012, April 2025.
In patients with Acute Myocardial Infarction related heart failure, the in‐hospital administration of ARNIs was associated with a reduced risk of MACEs and re‐hospitalizations for heart failure, as well as cardiac remodeling, compared to standard therapy.
Gianluca Di Pietro, Riccardo Improta, Paolo Severino, Andrea D'Amato, Lucia Ilaria Birtolo, Ovidio De Filippo, Antonio Lattanzio, Raffaele De Cristofaro, Giacchino Galardo, Fabrizio D'Ascenzo, Roberto Badagliacca, Gennaro Sardella, Maurizio Volterrani, Francesco Fedele, Carmine Dario Vizza, Massimo Mancone   +15 more
wiley   +1 more source

Pleiotropic Effects of Ticagrelor: Influence on CYP4F2 Gene and Protein Expression in HUVEC and HepG2, and Escherichia coli Bacterial Survival

Drug Design, Development and Therapy, 2022
Ugne Meskauskaite,1 Silvija Andruskeviciute,1 Ieva Ciapiene,1 Agne Giedraitiene,2 Vaiva Lesauskaite,1 Vacis Tatarunas1 1Institute of Cardiology, Lithuanian University of Health Sciences, Kaunas, Lithuania; 2Institute of Microbiology and Virology ...
Meskauskaite U, Andruskeviciute S, Ciapiene I, Giedraitiene A, Lesauskaite V, Tatarunas V   +5 more
doaj  

Contemporary NSTEMI management: the role of the hospitalist. [PDF]

, 2019
Non-ST-segment elevation myocardial infarction (NSTEMI) is defined as elevated cardiac biomarkers of necrosis in the absence of persistent ST-segment elevation in the setting of anginal symptoms or other acute event.
Amin, Alpesh, Cohen, Marc, Deitelzweig, Steven, DiLascia, Christopher, Fanikos, John, Kaatz, Scott, Pollack, Charles V, Slattery, David, Tuder, Regan, Wang, Tracy   +9 more
core   +1 more source